Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy

Biomarkers that facilitate the prediction of disease recurrence in prostate cancer (PCa) may enable physicians to personalize treatment for individual patients. In the current study, PD-1 (PDCD1) promoter methylation was assessed in a cohort of 498 PCa patients included in The Cancer Genome Atlas (T...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncoimmunology
Asıl Yazarlar: Goltz, Diane, Gevensleben, Heidrun, Dietrich, Jörn, Ellinger, Jörg, Landsberg, Jennifer, Kristiansen, Glen, Dietrich, Dimo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2016
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5087295/
https://ncbi.nlm.nih.gov/pubmed/27853645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1221555
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller